Buy or sell Adimab stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Adimab Stock

Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.

About Adimab Stock

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Funding History

July 2007$6.0M
July 2007$2K
September 2007$5.9M
April 2008$3.2M
November 2008$4.0M
January 2010$8.2M
December 2010$4.0M
April 2012$14.0M
April 2012$0


General Counsel

Philip Chase

Director, Antibody Discovery & Optimization

Eric Krauland

Associate Director, Antibody Discovery and Bispecific Engineering

Robert Mabry

VP, Head, Business Development

Guy Van Meter

Founder, CEO

Tillman Gerngross

Co - Founder, Office Of The CSO & Chairman, SAB

K. Dane Wittrup

VP & Head, Computational Biology

Max Vasquez

Director, Open Innovation

Piotr Bobrowicz


Errik Anderson


Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Adimab or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 250K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: